Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial

2022 ◽  
Author(s):  
Qing Zhou ◽  
Ming Chen ◽  
Ou Jiang ◽  
Yi Pan ◽  
Desheng Hu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Locally Advanced ◽  
Small Cell ◽  
Small Cell Lung ◽  
Phase 3 ◽  
Double Blind ◽  
Multicentre Phase ◽  
Unresectable Stage

scholarly journals Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial

2014 ◽  
Vol 15 (1) ◽  
pp. 59-68 ◽  
Author(s):  
Charles Butts ◽  
Mark A Socinski ◽  
Paul L Mitchell ◽  
Nick Thatcher ◽  
Libor Havel ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Stage Iii ◽  
Small Cell Lung ◽  
Phase 3 ◽  
Double Blind
Sign in / Sign up

Export Citation Format

Share Document